drugset
drugset / Trial / NCT02079168

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

NCT02079168 ↗

Phase 2 Completed 16 enrolled RXi Pharmaceuticals, Corp.
RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.

Timeline

Start
2014-03
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject RXI-109 Unknown — —

Indications

keloid